In vitro activity of tigecycline against inpatient and outpatient isolates from a European population
Abstract number: P681
Hackel M., Bouchillon S., Johnson B., Badal R., Johnson J., Hoban D., Dowzicky M.
Objectives: Tigecycline, a member of a new class of antimicrobials (glycylcyclines), has been shown to have potent broad spectrum activity against most commonly encountered species responsible for community and hospital acquired infections. The T.E.S.T. Program surveyed the in vitro activity of tigecycline and comparator compounds against in-patient and out-patient pathogens from Europe for the period from 2004 to 2007.
Methods: A total of 16,451 clinical isolates from 93 testing sites in 22 European countries were tested. Minimum Inhibitory Concentration (MICs) were determined by each site using common broth microdilution panels and interpreted according to EUCAST guidelines.
Results: See the tables.
Conclusion: Tigecycline's in vitro activity was comparable to or greater than most commonly prescribed broad spectrum antimicrobials without any demonstrable change in activity between in-patient and out-patient bacterial study strains. Tigecycline's inhibitory activity against Enterobacteriaceae, and Acinetobacter spp. was comparable to imipenem. Against Gram-positive organisms, tigecycline's activity was comparable to linezolid and vancomycin.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|